|
Cell Proliferation:
AKT1; v-akt murine thymoma viral oncogene homolog 1, 14q32.32
AKT2; v-akt murine thymoma viral oncogene homolog 2, 19q13.1-q13.2
AKT3; v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma), 1q43-q44
CDKN2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4), 9p21
CDKN2B; cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4), 9p21
IKBKB; inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta, 8p11.2
IL1B; interleukin 1, beta, 2q14
IL1R1; interleukin 1 receptor, type I, 2q12
IL2; interleukin 2, 4q26-q27
IL2RA; interleukin 2 receptor, alpha, 10p15-p14
IL2RG; interleukin 2 receptor, gamma (severe combined immunodeficiency), Xq13.1
IL6; interleukin 6 (interferon, beta 2), 7p21
IL6ST; interleukin 6 signal transducer (gp130, oncostatin M receptor), 5q11
IRAK4; interleukin-1 receptor-associated kinase 4, 12q12
MAP3K7; mitogen-activated protein kinase kinase kinase 7, 6q16.1-q16.3
MAPK14; mitogen-activated protein kinase 14, 6p21.3-p21.2
MIF; macrophage migration inhibitory factor (glycosylation-inhibiting factor), 22q11.23
MLLT7; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 7, Xq13.1
MYD88; myeloid differentiation primary response gene (88), 3p22
NFKBIA; nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha, 14q13
PDPK1; 3-phosphoinositide dependent protein kinase-1, 16p13.3
PIK3C2A; phosphoinositide-3-kinase, class 2, alpha polypeptide, 11p15.5-p14
PIK3C2B; phosphoinositide-3-kinase, class 2, beta polypeptide, 1q32
PIK3C2G; phosphoinositide-3-kinase, class 2, gamma polypeptide, 12p12
PIK3CA; phosphoinositide-3-kinase, catalytic, alpha polypeptide, 3q26.3
PIK3CB; phosphoinositide-3-kinase, catalytic, beta polypeptide, 3q22.3
PIK3CD; phosphoinositide-3-kinase, catalytic, delta polypeptide, 1p36.2
PIK3CG; phosphoinositide-3-kinase, catalytic, gamma polypeptide, 7q22.3
PIK3R1; phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha), 5q13.1
PIK3R1OS; phosphoinositide-3-kinase, regulatory subunit 1, opposite strand, 5
PIK3R2; phosphoinositide-3-kinase, regulatory subunit 2 (p85 beta), 19q13.2-q13.4
PIK3R3; phosphoinositide-3-kinase, regulatory subunit 3 (p55, gamma), 1p34.1
PIK3R4; phosphoinositide-3-kinase, regulatory subunit 4, p150, 3q21.3
PIK3R5; phosphoinositide-3-kinase, regulatory subunit 5, p101, 17p13.1
PPARA; peroxisome proliferative activated receptor, alpha, 22q12-q13.1
PPARBP; PPAR binding protein, 17q12-q21.1
PPARD; peroxisome proliferative activated receptor, delta, 6p21.2-p21.1
PPARG; peroxisome proliferative activated receptor, gamma, 3p25
PPARGC1A; peroxisome proliferative activated receptor, gamma, coactivator 1, alpha, 4p15.1
PPARGC1B; peroxisome proliferative activated receptor, gamma, coactivator 1, beta, 5q32
PPRC1; peroxisome proliferative activated receptor, gamma, coactivator-related 1, 10q24.32
PROP1; prophet of Pit1, paired-like homeodomain transcription factor, 5q35.3
PTEN; phosphatase and tensin homolog (mutated in multiple advanced cancers 1), 10q23.3
RELA; v-rel reticuloendotheliosis viral oncogene homolog A, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3, p65 (avian), 11q13
RIPK1; receptor (TNFRSF)-interacting serine-threonine kinase 1, 6p25.2
RIPK2; receptor-interacting serine-threonine kinase 2, 8q21
RIPK3; receptor-interacting serine-threonine kinase 3, 14q11.2
RIPK4; receptor-interacting serine-threonine kinase 4, 21q22.3
RIPK5; receptor interacting protein kinase 5, 1q32.1
SHC1; SHC (Src homology 2 domain containing) transforming protein 1, 1q21
SHC2; SHC (Src homology 2 domain containing) transforming protein 2, 19p13.3
SHC3; src homology 2 domain containing transforming protein C3, 9q22.1-q22.2
SHCBP1; SHC SH2-domain binding protein 1, 16q11.2
SIRT1; sirtuin (silent mating type information regulation 2 homolog) 1 (S. cerevisiae), 10q21.3
STAT3; signal transducer and activator of transcription 3 (acute-phase response factor), 17q21.31
TNFAIP1; tumor necrosis factor, alpha-induced protein 1 (endothelial), 17q22-q23
TNFAIP2; tumor necrosis factor, alpha-induced protein 2, 14q32
TNFAIP3; tumor necrosis factor, alpha-induced protein 3, 6q23
TNFAIP8; tumor necrosis factor, alpha-induced protein 8, 5q23.1
TNFRSF1A; tumor necrosis factor receptor superfamily, member 1A, 12p13.2
TP53; tumor protein p53 (Li-Fraumeni syndrome), 17p13.1
TRADD; TNFRSF1A-associated via death domain, 16q22
TRAF1; TNF receptor-associated factor 1, 9q33-q34
TRAF2; TNF receptor-associated factor 2, 9q34
Cognitive Impairment:
APBB1; amyloid beta (A4) precursor protein-binding, family B, member 1 (Fe65), 11p15
APOE; apolipoprotein E, 19q13.2
APP; amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease), 21q21.2
PSEN1; presenilin 1 (Alzheimer disease 3), 14q24.3
PSEN2; presenilin 2 (Alzheimer disease 4), 1q31-q42
RGN; regucalcin (senescence marker protein-30), Xp11.3
Degenerative Processes:
BAX; BCL2-associated X protein, 19q13.3-q13.4
KL; klotho, 13q12
PARK2; Parkinson disease (autosomal recessive, juvenile) 2, parkin, 6q25.2-q27
UCHL1; ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase), 4p14
DNA Metabolism:
ATM; ataxia telangiectasia mutated (includes complementation groups A, C and D), 11q22-q23
BLM; Bloom syndrome, 15q26.1
ERCC2; excision repair cross-complementing rodent repair deficiency, complementation group 2 (xeroderma pigmentosum D), 19q13.3
ERCC8; excision repair cross-complementing rodent repair deficiency, complementation group 8, 5q12.1
GADD45A; growth arrest and DNA-damage-inducible, alpha, 1p31.2-p31.1
GADD45B; growth arrest and DNA-damage-inducible, beta, 19p13.3
GADD45G; growth arrest and DNA-damage-inducible, gamma, 9q22.1-q22.2
TOP1; topoisomerase (DNA) I, 20q12-q13.1
TOP2A; topoisomerase (DNA) II alpha 170kDa, 17q21-q22
TOP3A; topoisomerase (DNA) III alpha, 17p12-17p11.2
TOP3B; topoisomerase (DNA) III beta, 22q11.22
WRN; Werner syndrome, 8p12-p11.2
Heat Shock:
HSPA9B; heat shock 70kDa protein 9B (mortalin-2), 5q31.1
HSPCA; heat shock 90kDa protein 1, alpha, 14q32.33
Insulin Signaling / Metabolism:
FOXC2; forkhead box C2 (MFH-1, mesenchyme forkhead 1), 16q22-16q24
FOXD1; forkhead box D1, 5q12-q13
FOXO1A; forkhead box O1A (rhabdomyosarcoma), 13q14.1
FOXO3A; forkhead box O3A, 6q21
FOXO6; forkhead box protein O6, 1p34.1
FOXP1; forkhead box P1, 3p14.1
FOXP2; forkhead box P2, 7q31
FOXP4; forkhead box P4, 6p21.1
GHR; growth hormone receptor, 5p13-p12
GHRHR; growth hormone releasing hormone receptor, 7p14
IGF1; insulin-like growth factor 1 (somatomedin C), 12q22-q23
IGF1R; insulin-like growth factor 1 receptor, 15q26.3
IGF2; insulin-like growth factor 2 (somatomedin A), 11p15.5
IGF2R; insulin-like growth factor 2 receptor, 6q26
INS; insulin, 11p15.5
INSR; insulin receptor, 19p13.3-p13.2
INSRL; insulin receptor-like, 7p13-q22
INSRR; insulin receptor-related receptor, 1q21-q23
IRS1; insulin receptor substrate 1, 2q36
IRS2; insulin receptor substrate 2, 13q34
IRS3L; insulin receptor substrate 3-like, 7q22
IRS4; insulin receptor substrate 4, Xq22.3
MAPK1; mitogen-activated protein kinase 1, 22q11.2
MAPK3; mitogen-activated protein kinase 3, 16p12-p11.2
PBK; PDZ binding kinase, 8p21.2
PLK1; polo-like kinase 1 (Drosophila), 16p12.1
PLK2; polo-like kinase 2 (Drosophila), 5q12.1-q13.2
PLK3; polo-like kinase 3 (Drosophila), 1p34.1
POU1F1; POU domain, class 1, transcription factor 1 (Pit1, growth hormone factor 1), 3p11
RETN; resistin, 19p13.2
SLC2A4; solute carrier family 2 (facilitated glucose transporter), member 4, 17p13
SLC2A4RG; SLC2A4 regulator, 20q13.33
TNF; tumor necrosis factor (TNF superfamily, member 2), 6p21.3
mtDNA-encoded Proteins:
ATP6; mitochondrially encoded ATP synthase 6,
ATP8; mitochondrially encoded ATP synthase 8,
CO1; mitochondrially encoded cytochrome c oxidase I,
CO2; mitochondrially encoded cytochrome c oxidase II,
CO3; mitochondrially encoded cytochrome c oxidase III,
ND1; mitochondrially encoded NADH dehydrogenase 1,
ND2; mitochondrially encoded NADH dehydrogenase 2,
ND3; mitochondrially encoded NADH dehydrogenase 3,
ND4; mitochondrially encoded NADH dehydrogenase 4,
ND4L; mitochondrially encoded NADH dehydrogenase 4L,
ND5; mitochondrially encoded NADH dehydrogenase 5,
ND6; mitochondrially encoded NADH dehydrogenase 6,
Nuclear-encoded Mito-Proteins:
DGUOK; deoxyguanosine kinase, 2p13
ECGF1; endothelial cell growth factor 1 (platelet-derived), 22q13
ENDOG; endonuclease G, 9q34.1
OGG1; 8-oxoguanine DNA glycosylase, 3p26.2
PEO1; progressive external ophthalmoplegia 1, 10q23.3-24.3
POLG; polymerase (DNA directed), gamma, 15q25
POLG2; polymerase (DNA directed), gamma 2, accessory subunit, 17q
SLC25A4; solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4, 4q35
SSBP1; single-stranded DNA binding protein 1, 7q34
TFAM; transcription factor A, mitochondrial, 10q21
TK1; thymidine kinase 1, soluble, 17q23.2-q25.3
TK2; thymidine kinase 2, mitochondrial, 16q22-q23.1
TOP1MT; topoisomerase (DNA) I, mitochondrial, 8q24.3
UNG; uracil-DNA glycosylase, 12q23-q24.1
Stress and Inflammation / Thrombosis:
APC; adenomatosis polyposis coli, 5q21-q22
ASIP; agouti signaling protein, nonagouti homolog (mouse), 20q11.2-q12
CCL2; chemokine (C-C motif) ligand 2, 17q11.2-q21.1
CD14; CD14 antigen, 5q22-q32
CPB2; carboxypeptidase B2 (plasma, carboxypeptidase U), 13q14.11
CRP; C-reactive protein, pentraxin-related, 1q21-q23
F2; coagulation factor II (thrombin), 11p11-q12
F7; coagulation factor VII (serum prothrombin conversion accelerator), 13q34
F9; coagulation factor IX (plasma thromboplastic component, Christmas disease, hemophilia B), Xq27.1-q27.2
FGA; fibrinogen, A alpha polypeptide, 4q28
FGB; fibrinogen, B beta polypeptide, 4q28
FGG; fibrinogen, gamma polypeptide, 4q28
FLT1; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor), 13q12
MSRA; methionine sulfoxide reductase A, 8p23.1
NFKB1; nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), 4q24
PLAT; plasminogen activator, tissue, 8p12
PLAU; plasminogen activator, urokinase, 10q24
PLAUR; plasminogen activator, urokinase receptor, 19q13
PLG; plasminogen, 6q26
PRAP1; proline-rich acidic protein 1, 10q26.3
PROC; protein C (inactivator of coagulation factors Va and VIIIa), 2q13-q14
SERPINA1; serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1, 14q32.1
SERPINE1; serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1, 7q21.3-q22
SNCA; synuclein, alpha (non A4 component of amyloid precursor), 4q21
SOD1; superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)), 21q22.1
SOD2; superoxide dismutase 2, mitochondrial, 6q25.3
TAF6; TAF6 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 80kDa, 7q22.1
THBD; thrombomodulin, 20p12-cen
TLR1; toll-like receptor 1, 4p14
TLR2; toll-like receptor 2, 4q32
TLR3; toll-like receptor 3, 4q35
TLR4; toll-like receptor 4, 9q32-q33
TLR5; toll-like receptor 5, 1q41-q42
TLR6; toll-like receptor 6, 4p14
VEGF; vascular endothelial growth factor, 6p12
VEGFB; vascular endothelial growth factor B, 11q13
VEGFC; vascular endothelial growth factor C, 4q34.1-q34.3
Telomere Metabolism:
TERC; telomerase RNA component, 3q26
TERT; telomerase reverse transcriptase, 5p15.33
Other Longevity Proteins:
MORF4; mortality factor 4, 4q33-q34.1
Others:
ABT1; activator of basal transcription 1, 6p22.1
GAPD; glyceraldehyde-3-phosphate dehydrogenase, 12p13
|
|